Advertisement

Topics

Athersys, Inc. (ATHX) Upgraded to Buy by Zacks Investment Research

13:14 EDT 24 Aug 2017 | Topix

Zacks Investment Research currently has $1.75 price target on the biopharmaceutical company's stock. According to Zacks, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.

Original Article: Athersys, Inc. (ATHX) Upgraded to Buy by Zacks Investment Research

NEXT ARTICLE

More From BioPortfolio on "Athersys, Inc. (ATHX) Upgraded to Buy by Zacks Investment Research"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...